乳腺癌组织中耐药蛋白的表达及化疗耐药性的相关性研究

目的：探讨三种耐药蛋白GST-π，P—gP，Topo-Ⅱ在乳腺癌组织中的表达，比较分析三种耐药相关基因蛋白在不同临床特点的乳腺癌和不同分子分型乳腺癌组织中的表达差别，为临床治疗提供依据。方法：采用免疫组织化学HRP法检测60例LuminalA型；60例Her-2（＋）（其中含有Her一2阳性的LuminalB型）；46例三阴性乳腺癌组织中GST-π，P—gP和Topo-Ⅱ的表达，并结合病理特点进行分析。结果：GST-π、P—gP、Topo—Ⅱ的表达与病人年龄、肿瘤大小无关。GST-π、P—gP在“Her-2（＋）组”及“三阴组”表达率高于“LuminalA组”的表达率，呈正相关（P〈0．05）。GsT-π的表达与组织学分级、激素受体表达、乳腺癌的分子分型有关，有统计学意义（P〈0．05）。P—gP的表达与淋巴结转移与否、HER-2表达状况、乳腺癌的分子分型呈正相关（P〈0．05）；Topo—Ⅱ与淋巴结转移与否呈正相关（P〈0．05）。结论：GST-π、P—gP高表达是乳腺癌多药耐药发生的高危因素；Topo—Ⅱ其表达量的高低与化疗药物作用正相关，与肿瘤的恶性程度正相关。

EXPRESSION AND CHEMORESISTANCE-RELATED RESEARCH OF RESISTANCE-RELATED PROTEIN IN BREAST CANCER

Objective： Explore the three resistance protein GST-π, P-gp, Topo-Ⅱ expression in breast cancer, comparative analysis of a variety of resistance-associated protein in the different clinical characteristics of breast cancer and different molecular classification of breast cancer tissue expression of differences, to provide a basis for clinical treatment. Methods： Immunohistochemistry was used to HRP was detected 60 cases of luminal A subtype;60 cases of Her-2 （＋） （containing Her-2 positive Luminal B subtype） ;46 cases of triple negative breast cancer tissue,the expression of GST-π,P-gp and Topo-Ⅱ, combined with the pathological features were analyzed. Results：The expression of GST-π, P-gp,Topo-Ⅱ with patient age, tumor size, express no statistical significance. The expression of GST-π,P-gp in the Her-2（＋） group and the triple negative group expression is higher than Luminal A subtype rates was positively correlated （P〈0.05）. The expression of GST-π and histological grade, hormone receptor expression, and molecular classification of breast cancer was positively correlated （P〈 0.05 ）. The expression of P-gp and lymph node metastasis, HER-2 expression, molecular classification of breast cancer was positively correlated （ P 〈 0.05 ） ; The expression of Topo - Ⅱ and lymph node metastasis is related to statistically significant （ P 〈 0.05 ）. Conclusion： GST - π, P - gp was highly expressed in breast cancer more than to be the resistance occurring risk factors;The expression level of Topo-Ⅱ with the chemotherapy drugs was positively correlated, related to a positive correlation with the degree of malignancy.